Surgery vs Medicine for Diverticulitis
(COSMID Trial)
Trial Summary
What is the purpose of this trial?
This trial compares surgery (removing part of the colon) with a combination of medications and lifestyle changes for patients whose diverticular disease affects their quality of life. It aims to find out which treatment helps these patients feel better and live more comfortably.
Do I need to stop my current medications for the trial?
The trial protocol does not specify if you need to stop taking your current medications. However, if you are taking medications for inflammatory bowel disease or irritable bowel syndrome, you may not be eligible to participate.
What data supports the effectiveness of this treatment for diverticulitis?
Recent studies suggest that non-surgical management, which includes medical and conservative treatments, can be as effective as surgery for many patients with uncomplicated diverticulitis. However, surgery may still be necessary for those with complicated cases or for immunocompromised patients, where medical treatment often fails.12345
Is surgery or medical management for diverticulitis safe?
Research suggests that non-surgical management, which includes antibiotics and supportive care, is safe for over 70% of patients with diverticulitis. For those needing surgery, minimally invasive procedures like laparoscopic colectomy have shown improved safety outcomes, especially in patients with other health issues.678910
How does the treatment of surgery vs medicine for diverticulitis differ from other treatments?
This treatment is unique because it compares medical management, which often involves antibiotics and dietary changes, with surgical options like partial colectomy (removal of part of the colon), which is typically reserved for patients with a high risk of recurrence or when conservative treatments fail. The choice between these approaches depends on the severity of the condition and the patient's overall health.25111213
Research Team
David R Flum, MD
Principal Investigator
University of Washington
Eligibility Criteria
Adults over 18 with a history of recurrent diverticulitis confirmed by CT and colonoscopy, who are currently symptom-free or have persistent symptoms for more than 3 months after an episode. Not eligible if they have right-sided diverticulitis, take certain medications for bowel diseases, had previous surgeries for diverticulitis, are pregnant or planning to become pregnant soon, or have conditions that rule out surgery.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants are randomized to either elective segmental colectomy or best medical management
Follow-up
Participants are monitored for quality of life and symptoms using the GIQLI at 6, 9, and 12 months
Treatment Details
Interventions
- Medical Management (NA)
- Partial Colectomy (NA)
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Washington
Lead Sponsor
Dr. Timothy H. Dellit
University of Washington
Chief Executive Officer since 2023
MD from University of Washington
Dr. Anneliese Schleyer
University of Washington
Chief Medical Officer since 2023
MD, MHA
Patient-Centered Outcomes Research Institute
Collaborator
Nakela L. Cook
Patient-Centered Outcomes Research Institute
Chief Executive Officer since 2020
MD, MPH
Harv Feldman
Patient-Centered Outcomes Research Institute
Chief Medical Officer
MD, MSCE